Skip to main content

Table 2 Clinical characteristics of patients enrolled in the study at T0 and T12

From: Glycosylation deficiency of lipopolysaccharide-binding protein and corticosteroid-binding globulin associated with activity and response to treatment for rheumatoid arthritis

 HVERA 
n9090 
Female7272 
Age—mean (range)34.4 (19–51)34.1 (19–50) 
RF+ %66 
Anti-CCP+ %68 
Treatment % T0T12
Corticoids11
MTX93
Biologics24
Hydroxychloroquine5
Clinical measures Mean (range)_T0Mean (range)_T12
DAS28-CRP4.4 (7.3–1.21)2.7 (5.3–1.2)
SDAI23.3 (70.4–0)9.5 (77–0.1)
CDAI21 (65.2–0)8.2 (30–0)
TJC9 (33–0)2.9 (19–0)
TJC286.7 (26–0)2.3 (19–0)
SJC6.3 (27–0)1.3 (8–0)
SJC284.8 (26–0)1.1 (7–0)
CRP mg/dL2.3 (26–0.09)0.6 (10–0.02)
HAQ1 (2.4–0)0.7 (2.8–0)
VAS med41.1 (89–10)15.9 (70–0)
VAS pat53.9 (100–0)32.2 (90–0)
VAS pain55 (100–0)31 (90–0)
VAS fatigue54.9 (100–0)41.1 (96–0)
  1. HV healthy volunteers, ERA early rheumatoid arthritis, DAS28-CRP disease activity score 28 joints, SDA: Simplified Disease Activity Index, CDAI Clinical Disease Activity Index, TJC28 28-Tender Joint Count, SJC28 28-Swollen Joint Count; HAQ Health Assessment Questionnaire, VAS Visual Analogue Scale